Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 5/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651369 | 0.77 | LOX (0.35) | L3MBTL1LOXLOXL2 | |
| SCHEMBL12630189 | 0.75 | SIGMAR1 (0.45) | KMT2AL3MBTL1LOXLOXL2SMN1; SMN2 | |
| SCHEMBL1163831 | 0.72 | THRB (0.56) | KMT2ASMN1; SMN2MAPK1ALDH1A1TSHR | |
| SCHEMBL12630271 | 0.70 | KMT2A (0.47) | KMT2AL3MBTL1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10684316 | 0.70 | TDP1 (0.39) | L3MBTL1MAPK1TSHRLMNAHTT | |
| SCHEMBL29512727 | 0.68 | CA12 (0.41) | KMT2AL3MBTL1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL25698177 | 0.68 | SMN1; SMN2 (0.38) | L3MBTL1SMN1; SMN2ALDH1A1LMNATP53 | |
| SCHEMBL12228299 | 0.68 | KMT2A (0.54) | KMT2ASMN1; SMN2ALDH1A1TSHRLMNA | |
| SCHEMBL27661015 | 0.67 | SMN1; SMN2 (0.33) | KMT2ASMN1; SMN2ALDH1A1TSHRLMNA | |
| SCHEMBL5648958 | 0.66 | SMN1; SMN2 (0.53) | KMT2AL3MBTL1SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| CN-1863793-A | Cyclic tertiary amine compound | SANKYO CO (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | KMT2A 2948/4885L3MBTL1 4263/4885LOX 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.